Regeneron Pharmaceuticals (REGN) Non-Current Assets (2009 - 2026)

Regeneron Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $22.7 billion for Q1 2026.

• In Q1 2026, Non-Current Assets rose 13.45% year-over-year to $22.7 billion; the TTM figure through Mar 2026 stood at $88.7 billion (up 19.63% YoY), while the FY2025 annual figure was $22.5 billion, up 18.0% from the prior year.
• Non-Current Assets was $22.7 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $22.5 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $22.7 billion in Q1 2026 to a low of $11.7 billion in Q2 2022.
• Historically, Non-Current Assets has averaged $16.6 billion across 5 years, with a median of $15.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets jumped 56.05% in 2022, then climbed 2.03% in 2023.
• A 5-year view of Non-Current Assets shows it stood at $13.3 billion in 2022, then advanced by 2.03% to $13.6 billion in 2023, then soared by 40.42% to $19.1 billion in 2024, then advanced by 18.0% to $22.5 billion in 2025, then gained by 0.54% to $22.7 billion in 2026.
• The last three Non-Current Assets figures came in at $22.7 billion (Q1 2026), $22.5 billion (Q4 2025), and $22.2 billion (Q3 2025), per Business Quant data.